key: cord-0825318-9fve3jok
authors: Du, J.; Zhang, D.; May, H.; Loginova, Y.; Chu, E.; Madej, R.; Lu, C. M.; Pathakamuri, J. A.; Kuebler, D.; Neves, J. V.; Zhang, A.; Sha, M. Y.
title: A Single Drop of Fingerstick Blood for Quantitative Antibody Response Evaluation After SARS-CoV-2 Vaccination
date: 2021-04-17
journal: nan
DOI: 10.1101/2021.04.11.21255278
sha: d7f47188dd6a5abe2bb5bcd5276d182b767c157f
doc_id: 825318
cord_uid: 9fve3jok

Among several COVID vaccines that have been approved, the Moderna and Pfizer-BioNTech vaccines are mRNA vaccines that are safe and highly effective at preventing COVID-19 illness. Studies have demonstrated that neutralizing antibody responses elicited by these vaccines correlate strongly with antibodies measured by immunoassays such as ELISA. To monitor the antibody level duration of vaccine-induced immune responses in vaccinated population, cost-effective and easily implementable antibody testing methodologies are urgently needed. In this study, we evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for a high-throughput and quantitative anti-SARS-CoV-2 spike (S1) IgG antibody immunoassay. A total of 50 voluntary subjects participated and donated fingerstick blood samples before and after receiving the Moderna mRNA vaccine. Among all individuals tested, no anti-SARS-CoV-2 S1 IgG antibody was detected before vaccination and on day 7 after receiving the first vaccine dose. On day 14 after the first dose, a significant amount of anti-SARS-CoV-2 S1 IgG antibody was detected in all participants samples. By the end the third week from the first dose, the median anti-SARS-CoV-2 S1 IgG concentration increased to 44.9 ug/mL. No anti-SARS-CoV-2 nucleocapsid (N) protein IgG antibody was detected in any of the participants during the study period, indicating that the anti-SARS-CoV-2 S1 IgG assay is specific for the mRNA vaccine induced antibodies. Comaprison of venous blood plasma and fingerstick blood for anti-SARS-CoV-2 S1 IgG shown a higher correlation. Furthermore, the fingerstick blood dried swab samples are stable for at least 4 days. In summary, we demonstrated that a single drop of fingerstick blood collected with flocked swab can be used for quantitative detection and monitoring of anti-SARS-CoV-2 spike IgG responses after receiving COVID-19 vaccination. This testing platform does not require venous blood draw and can be easily implemented for large scale antibody testing in vaccinated populations.

workers demonstrated significant protection from asymptomatic and symptomatic infection with protection increasing from day 10 onwards, and plateauing after 21 days after first dose 15 . Therefore, the anti-SARS-CoV-2 spike (S) specific IgG antibodies measured by ELISA could be used to predict protection after SARS-CoV-2 infection or COVID-19 vaccination based immunity.

Notably, Karp et al 16 measured finger-prick dried blood spot based SARS-CoV-2 antibody assay and demonstrated that results of dried fingerstick blood correlated well with that of paired plasma samples. Iyer et al 17 further confirmed that anti-RBD IgG dried blood spots (DBS) measurements had a high degree of linear correlation with plasma. As more vaccines are being made available for large scale vaccination, it is highly desirable to have a simple and convenient test for detecting anti-SARS-CoV-2 IgG antibody. In this study, we evaluated the feasibility of using a single drop of fingerstick blood sample collected with nylon flocked swabs for an quantitative detection of anti-SARS-CoV-2 S1 IgG antibody, and demonstrated that fingerstick blood is sufficient for quantitative measurement of the antibody responses after receiving a mRNA COVID-19 vaccine.

Deidentified fingertip blood samples were used in the study. All fingerstick blood specimens were collected in January -March 2021 and were tested at DiaCarta's CLIA laboratory. Other than anti-SARS-CoV-2 S1 IgG results (positive or negative), no other information were included in study analysis and no patient clinical chart reviews were performed. This study was approved by the Institutional Review Board (IRB) at Franciscan University of Steubenville (IRB #2021-05) as a no-subject contact study with waiver of consent and as exempt under category 4.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint

Fingerstick blood dried swab collection kit contains disposable lancets, alcohol pads, a swab, one 1 mL microtube and instruction sheet. First, clean the desired puncture site using alcohol prep pad.

Remove the cap of safety lancet and stick the fingerstick with lancet. Squeeze fingerstick to obtain one drop of blood (approx. 20µL). Next, wipe the blood onto the stick of nylon flocked swab (Kangjian, Jiangsu, China). Lastly, place the swab into screw cap tube, break swab at the score mark, and leave the stick of swab in screw cap tube. A guidance diagram show in Supplementary 

The recombinant SARS-CoV-2 Spike protein S1 (RBD, His Tag) containing 330-524 amino acids of Spike protein and the SARS-CoV-2 nucleocapsid (N) protein (PMC 827, NP2) were produced from HEK293 suspension cells (ProMab Biotechnologies Inc, CA). SARS-CoV-2 Spike S1 Antibody (human chimeric, IgG isotype) was purchased from GenScript Biotech Corporation (Piscataway, NJ). PE conjugated anti-human IgG Fc antibody was purchased from BioLegend (San Diego, CA). MagPlex Microsphere and xMAP ® Antibody Coupling (AbC) kit were purchased from Luminex (Austin, TX). Hemoglobin (human), bilirubin and EDTA were purchased from Sigma-Aldrich (St. Louis, MO).

First, 300uL of PBS-1% BSA buffer was added to the 1mL tube that contained one drop of fingerstick blood in dried swab and waited for 5 minutes. Then briefly vortex the tube to release the blood into the buffer. The inoculated buffer is used for IgG testing. Principle of the assay was shown in Figure 1 . Recombinant spike protein 1 (S1) RBD was covalently coupled to the surface of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint MagPlex ® Microspheres (magnetic beads) via a carbodiimide linkage using xMAP ® Antibody Coupling (AbC) kit. S1 RBD protein coated magnetic beads and human specimens were mixed and incubated at room temperature for 1.0 hour. If present, the IgG antibodies in specimen against S1 RBD protein (the antigen) will bind to the coated magnetic beads. After washing, PE conjugated anti-human IgG antibody was added to the reaction mixture and incubated at room temperature for 0.5 hours. After another washing, PE fluorescence of each well in a 96-well microplate was measured on MAGPIX ® instrument for Median Fluorescence Intensity (MFI). Interpretation of the testing results was performed by calculating the MFI ratio of each sample to the average MFI of two blank wells included in each test run.

all the subjects tested positive for anti-SARS-CoV-2 S1 IgG, detection rate was 100%. Among the subjects tested, we further quantitatively analyzed the SARS-CoV-2 S1 IgG testing results of 15 individuals (age: 22~58 years, median 35 years; 10 males, 5 females). As shown in Table 2 , no anti-SARS-CoV-2 S1 IgG antibody was detected before vaccination and on day 7 post first dose of vaccine (Moderna). By the ends of the second week and the third week after receiving the first dose, a significant amount of SARS-CoV-2 IgG antibody was detected in all individuals. The lowest levellevel detected was 0.54 µg/mL, while the highestlevels detected were 59.01 µg/mL, with the median being 20.78 µg/mL of IgG antibody. This data indicates that the fingerstick bloodbased testing method is sufficient for detecting and monitoring the development of anti-SARS-CoV-2 Spike IgG antibody after vaccination.

It was noted that, although the median value of IgG concentration in individuals 2 weeks after the first dose of vaccine was similar to those in asymptomatic individuals without known exposure to SARS-CoV-2 but confirmed by RT-qPCR late, on week 3 post vaccination, the median value of IgG level was remarkably increased (2.2 µg/mL, 2.8 µg/mL and 44.9 µg/mL for 1, 2 and 3 weeks, respectively. see Figure 2 ), indicating that COVID-19 mRNA vaccine is more efficient in inducing IgG antibody responses than asymptomatic SARS-CoV-2 infection.

Notable, second dose boost the anti-SARS-CoV-2 S1 IgG from average 8525 MFI (3 weeks) up to 10752 MFI in the first week ( Figure 3 ). Gradually, the average IgG increases to 13383 MFI in 4 weeks. It indicates that anti-SARS-CoV-2 S1 IgG achieves a high levele after two months vaccination.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint

We examined the relationship between IgG levels detected in fingertip blood samples either stored in EDTA tube or onto flocked swab. Five of paired fingerstick blood samples were tested in parallel. The MFI signals of each paired samples from vaccinated donators were compared side by side. Overall, the samples with EDTA showed higher signal than the dried swab samples.

Nonetheless, between the two sample types, the signals are highly correlated with an R 2 of 0.98 ( Figure 4 ).

We also compared the ratio between the signal intensity from pairs of venous plasma samples and dried swab samples which it came from vaccinated donators. Shown in Table 3 is the side by side comparison between the two sample type of five pair of vaccinated donators. In average, the MFI in plasma samples are about 4 time higher than that of fingerstick blood dried swab samples. The higher signals in plasma samples are expected as plasma obtained from venous blood contains a higher concentration of IgG antibodies than the more diluted fingerstick whole blood.

Unsurprisingly, a highly correlation between plasma and fingerstick blood dried swab were observed ( Figure 5 ).

To affirm the reported MFI signals were indeed specific for the SARS-CoV-2 Spike protein IgG antibodies elicited by mRNA vaccine, five samples were also tested using microspheres conjugated with SARS-CoV-2 nucleocapsid protein (N protein) and SARS-CoV-2 Spike RBD protein coupled microspheres separatly. As shown in Table 4 , for these five samples from . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint individuals vaccinated with Moderna SARS-CoV-2 mRNA vaccine, Spike RBD protein coupled microspheres detected high signal with the ratio greater than 200 (the cutoff value is 13.2) while the signal generated by N protein coupled microspheres was close to the background.

To test the stability of fingerstick blood collected using nylon flocked swabs and stored at room temperature (20±5 °C), total 7 of dried swab samples were tested on day 1, day 2, and day 4 at room temperature. As shown in Table 5 , the samples were stable for at least 4 days at room temperature.

We have demonstrated that an at home fingerstick blood collected on flocked dry swab is comparable to fingerstick blood collected into EDTA tube for anti-SARS-CoV-2 Spike IgG detection after full vaccination. A single drop of fingerstick blood with dried swab also has higherly correlation with venous plasma specimen for evoluation of anti-SARS-CoV-2 S1 IgG level. This approach is more convenient for end users, because there is no need for users to visit healthcare facility or a diagnostic laboratory. Furthermore, a singl drop of fingerstick blood was successfully applied to a quantitative anti-SARS-CoV-2 spike IgG assay, which can be used for monitoring the antibody response status overtime after full vaccination with COVID mRNA vaccine.

Our study indicated that 3 weeks after receiving the first dose of mRNA vaccine, a significant amount of anti-SARS-CoV-2 S1 IgG antibody can be detected in most individuals at an average of 44.9 ug/mL, comparedto their basilines before vaccination; with the execption of three people who . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint are over 80 years old. This result is consistent in concordance with a recent report that after of vaccination the antibody response was increased up to 1016 AUC on days 13-16, compared to 1 AUC on days 0-4 days after receiving vaccine, using an ELISA platform 8 . These results demonstrated that a single drop of fingerstick blood-based testing method is sufficient for quantitative detecting and monitoring the development of anti-SARS-CoV-2 Spike IgG antibody after vaccination.

Notably, this assay is specific for vaccine elicited anti-SARS-CoV-2 S1 IgG antibody and does not reactive to anti-SARS-CoV-2 nucleocapsid (N) antibody, allowing us to distinguish vaccination from infection because SARS-CoV-2 S1 mRNA vaccine only stimulates anti-SARS-CoV-2 spike IgG antibody response but not anti-SARS-CoV-2 N protein IgG antibody. This will be useful with identifying vaccinated idividuals from infected idividuals and recovered patients if we apply two tests (two wells of 96 wellplate) with S1 coated beads and N-coated beads separately for each individual sample.

We tested more than 50 voluntary subjects in this study and observed no detectable anti-SARS-CoV-2 IgG before vaccination and during the first week among inviduals who had not been previously diagnosed, whereas the antibody became detectable 2 weeks after the first dose, averaging 5000 MFI. The antibody response increased to about 12000-13000 MFI by 7-8 weeks (i.e., 3-4 weeks after second vaccine dose, Figure 3) . Notably, one individual infected with COVID-19 in 2020 whose IgG signal intensity jumped from 1300 MFI to over 15000 MFI whitin 1 week after first dose vaacination. This confirm seropositive persons has higher respond after first dose 8 . Marot et al 19 reported that anti-S IgG and anti-RBD IgG antibody levels in previously confirmed COVID-19 patients did not change significantly between 3 week and 3 months, despite . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2021. ;  a slight increase at 2 months. Based on our data, the vaccine-induced IgG antibody responses appear to follow the same course. In addition, SARS-CoV-2 neutralization (NT50) assay has demonstrated significant correlation with all antibodies measured by immunoassays IgGs including anti-S-BRD IgG 20 . Taken together, high levels of anti-SARS-CoV-2 spike IgG antibodies likely imply protective immunity against SARS-COV-2.

We found that all 3 subjects with undetectable anti-S IgG 2, two weeks after vaccination, the first vaccine dose were samples from over 80 years of age old. This observation suggests that not all https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399external icon . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint Week after Vaccination . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint Fingerstick blood on dried swab (MFI)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 17, 2021. ; https://doi.org/10.1101/2021.04.11.21255278 doi: medRxiv preprint

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

A human monoclonal antibody blocking SARS-CoV-2 infection

A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

A High-throughput Anti-SARS-CoV-2 IgG Testing Platform for COVID-19

Marot et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected